Drugs / 3D-Tissue Engineered Bone Equivalent
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03103295 | Nov 2015 → Dec 2018 | disease of bone structure | A.A. Partners, LLC | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3D-Tissue Engineered Bone Equivalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03103295 ↗ |
| Modality | Cell therapy | “autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs)” NCT03103295 ↗ |